Oncology

Back to articles

New study supports expanded abiraterone indication, shows survival benefit in metastatic prostate cancer

KEY POINT

In men with metastatic castration-resistant prostate cancer who had not received chemotherapy, abiraterone (Zytiga—Janssen) plus prednisone significantly improved radiographic progression-free survival and demonstrated a trend toward improved overall survival, as compared to prednisone alone.

SOURCES

Ryan CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368:138–48.